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Abstract Cell-based therapies for treating insulin-dependent
diabetes (IDD) can provide a more physiologic regulation of
blood glucose levels in a less invasive fashion than daily insulin
injections. Promising cells include non-L cells genetically engi-
neered to secrete insulin in response to physiologic cues; respon-
siveness can be introduced at the transcriptional level to regulate
preproinsulin (PPI) mRNA biosynthesis. However, these cells
exhibit sluggish secretion dynamics, which is not appropriate
for achieving euglycemia in higher animals and, eventually, hu-
mans. In this work, we have engineered the PPI mRNA so as to
destabilize it through nonsense-mediated mRNA decay (NMD).
When expressed under transcriptional regulation in HepG2 hep-
atomas, the engineered PPI mRNA level and of the insulin
secretion rate declined faster upon switching o¡ transcription,
compared to the one-copy non-engineered control. Our work
provides a simple and straightforward method to improve the
dynamics of transcriptionally regulated insulin secretion, which
can be a useful tool in developing cell-based therapies for IDD.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Hepatoma; Insulin secretion; Nonsense mRNA;
Pancreatic substitute
1. Introduction
Genetic engineering of non-L cells for glucose-responsive
insulin secretion o¡ers signi¢cant promise in developing a
cell-based therapy for insulin-dependent diabetes (IDD). Re-
sponsiveness to physiologic stimuli is introduced at the gene
transcription level by using promoters up-regulated by glucose
and possibly down-regulated by insulin [1^5]. Based on this
concept, glucose-regulated insulin expression has been
achieved in streptozotocin (STZ)-induced diabetic rodents
[2^5]. Although these results are promising, the sluggishness
in secretion dynamics of transcriptionally controlled cells
makes them inappropriate for glycemic regulation in higher
animals and, eventually, humans. Of particular signi¢cance is
the slow dynamics of secretion down-regulation, which results
in the cells secreting insulin long after the stimulus has been
removed and may thus revert diabetes to hyperinsulinemia
and hypoglycemia, a serious pathological condition.
It has been suggested that the prolonged stability of pre-
proinsulin (PPI) mRNA causes the sluggishness of secretion
down-regulation [6,7]. Although prior reports on the PPI
mRNA half-life in non-L cells are limited, data from normal
and transformed L cells strongly indicate that the stability of
PPI mRNA is a limiting factor in expediting secretion down-
regulation. In isolated primary rat islets, the half-life of PPI
mRNA was estimated to be 77 h under high glucose (17 mM)
and 29 h under low glucose concentration (3.3 mM) [8]. In
LTC-3 insulinomas, there was only marginal PPI mRNA deg-
radation over 24 h after transcription was stopped [9], while
the half-life of PPI mRNA in RIN-5F insulinomas was found
to be 58 and 26 h under high (20 mM) and low (3 mM)
glucose concentration, respectively [8].
Recently, nonsense-mediated mRNA decay (NMD) has re-
ceived signi¢cant attention because of its biological and med-
ical importance [10^13]. Mutant mRNAs with premature stop
codons can be detected by cells via a surveillance mechanism,
and are subjected to NMD [14,15]. Although NMD has prob-
ably evolved to eliminate erratic mRNAs, it also o¡ers an
interesting approach to destabilize genetically engineered
mRNA.
In this work, we investigated the destabilization of PPI
mRNA through engineering NMD, and its e¡ect on the dy-
namics of insulin secretion from recombinant HepG2 hepato-
mas. The implications of our ¢ndings in producing appropri-
ately secreting non-L cells with transcriptional regulation of
insulin expression are discussed.
2. Materials and methods
2.1. Plasmids for insulin expression
Vectors A^E in Fig. 1 are ¢ve plasmids constructed to systemati-
cally increase insulin expression in HepG2 cells. Human PPI cDNA
wild-type, furin-compatible with furin cleavage sites at the B^C and
C^A junctions, and furin-compatible with His B10-to-Asp mutation
(B10 mutation) were all generous gifts from Genentech (San Francis-
co, CA, USA) [16]. The backbone of insulin expression plasmids
originated from an 1822 bp BglII/BamHI fragment of plasmid pRL/
Null (Promega, Madison, WI, USA). A 508 bp XbaI/BamHI restric-
tion fragment containing both the simian virus 40 (SV40) late poly-
adenylation and SV40 enhancer signals from plasmid pGL3-control
(Promega) was used to replace the SV40 late polyadenylation signal in
pRL/Null to prepare the plasmid with the SV40 enhancer. The human
cytomegalovirus (CMV) promoter used to drive insulin gene was ob-
tained from an 883 bp BglII/NheI restriction fragment of plasmid
pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA). The CMV promoter
was connected to the BglII and SpeI sites of pRL/Null to prepare the
plasmid with an intron, or to the BglII and NheI sites to prepare the
plasmid without an intron. Di¡erent versions of XbaI/XbaI PPI
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cDNA fragment were connected to the backbones using NheI and
XbaI sites.
The backbone of the tet-responsive insulin expression plasmid was
obtained from a 2074 bp XhoI/XbaI fragment of plasmid pRL/Null
(Promega). The tetracycline-responsive promoter was obtained from a
448 bp XhoI/EcoRI restriction fragment of plasmid pTRE2pur (Clon-
tech, Palo Alto, CA, USA). This promoter was inserted into the
multiple cloning sites of pRL/Null. For the control plasmid contain-
ing one copy of insulin gene, a 360 bp XbaI/XbaI restriction fragment
containing the furin-compatible insulin gene with B10 mutation was
connected to the backbone using NheI and XbaI sites (vector F). For
the engineered plasmid, two additional copies of the insulin gene were
consecutively inserted to the backbone via the XbaI site with the same
head^tail con¢guration (vector G). After transcription, the engineered
PPI mRNA would contain three consecutive copies of the insulin gene
with stop codons in the middle of the transcript. Translation is ex-
pected to stop in the middle of the engineered PPI mRNA and induce
NMD. The XhoI/XhoI restriction fragments of the Clontech plasmids
cat# K1620-A and K1621-A were used to prepare plasmids pTet-O¡
and pTet-On, respectively.
2.2. Cell culture and transfection
HepG2 human hepatoma cells (ATCC, Manassas, VA, USA) were
grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum, 1.1 mg/ml sodium pyruvate
and 100 units/ml penicillin/streptomycin at 37‡C in a 5% CO2/95%
air humidi¢ed atmosphere. Approximately 106 cells were seeded in
each 9.6 cm2 well of 6-well plates and fed with 2 ml culture medium
for 8^12 h prior to transfection. All transfections were carried out
with FUGENE 6 reagent (Roche, Indianapolis, IN, USA) following
the manufacturer’s directions. For each well, HepG2 cells were trans-
fected for 24 h with the plasmid DNA cocktail (2.1 Wg or 2.25 Wg) and
6 Wl of FUGENE 6 reagent. Unless otherwise speci¢ed, transfected
cells were incubated in culture medium for another 24^36 h for re-
covery. Cells were then washed and incubated with culture medium
for two consecutive 1-h periods to stabilize insulin secretion before
any tests.
2.3. Systematic increase of insulin expression
HepG2 cells were transiently transfected using 2 Wg of test plasmid
(Fig. 1, vector A, B, C, D or E) and 0.1 Wg of plasmid pGL3-control
(Promega) for luciferase expression as internal standard according to
the procedure described in Section 2.2. Cells were then incubated for
1 h in culture medium, which was collected to assay for secreted
insulin. Cells were detached using 2.5 ml 0.25% trypsin solution sup-
plemented with 5 mg of collagenase type II for luciferase assay and
cell counting.
2.4. Dynamic insulin expression
HepG2 cells were transiently co-transfected using 2 Wg of plasmid
pTet-O¡ (or pTet-On) and 0.25 Wg of the control or engineered PPI
mRNA expression plasmid (Fig. 1, vectors F, G). Tet-O¡ transfected
cells in parallel cultures were incubated in doxycycline (DOX)-free
medium or in medium with 1 Wg/ml DOX for 24^36 h. Media were
renewed, and cells were incubated for an additional 1 h during which
insulin secretion was measured; cells were then lysed for quantitative
mRNA assay. To study the dynamics of insulin gene down-regulation,
Tet-O¡ transfected cells were switched from DOX-free medium to
1 Wg/ml DOX medium for 8 h. Every hour, culture medium was
renewed and collected for insulin assay. Every 2 h, cells were lysed
for quantitative mRNA assay. To dynamically regulate insulin secre-
tion using the Tet-On system, Tet-On transfected cells were switched
from DOX-free medium to 1 Wg/ml DOX medium for 1 h, washed
four times, then incubated with DOX-free medium for 7 h, and the
steps were repeated. Every hour, culture medium was renewed and
collected for insulin assay.
2.5. Translation inhibition test
Tet-O¡ transfected HepG2 cells were washed once, then exposed to
DOX-free medium with 28 Wg/ml cycloheximide for 4 h [17]. The time
of addition of cycloheximide-containing medium was time 0. To re-
sume translation, cells were washed four times, then incubated with
DOX-free, cycloheximide-free medium for two consecutive 4-h peri-
ods. At 0, 4, 8, and 12 h, cells were lysed for quantitative mRNA
assay.
2.6. Assays
Fire£y luciferase activity from the internal control vector pGL3-
control was measured using the luciferase assay system (Promega)
following the manufacturer’s protocol and using an LS 5000 scintilla-
tion counter (Beckman, Fullerton, CA, USA). Secreted insulin was
measured by human insulin speci¢c radioimmunoassay (RIA) kit
(LINCO Research, St. Charles, MI, USA). The primary antibody in
the kit cross-reacts with proinsulin at less than 0.2%. Radioactivities
were determined in Auto-Gamma Counting System, Cobra II (Pack-
ard, Meriden, CT, USA). The change of intracellular PPI mRNA
level was quanti¢ed by the TaqMan real-time polymerase chain reac-
tion (PCR) technique (Applied Biosystems, Foster City, CA, USA).
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Valencia,
CA, USA); cDNA was then synthesized using avian myoblastosis
virus (AMV) reverse transcriptase kit (Promega) to prepare templates
for TaqMan real-time PCR. The expression levels of PPI mRNA and
of the internal reference tTA (tetracycline-responsive transcriptional
activator, from co-transfected plasmid pTet-O¡) mRNA were mea-
sured using probes labeled with 6FAM1 and VIC1 (Applied Biosys-
tems), respectively, in separate tubes. The primers and probes (Table
1) were designed using Primer Express software (Applied Biosystems).
Measuring PPI mRNA-FAM and tTA mRNA-VIC permitted correc-
tion of discrepancies from di¡erences in sample preparation and
transfection e⁄ciencies. PCRs were performed with the TaqMan Uni-
versal PCR Master Mix and the ABI Prism 7700 Sequence Detection
System (Applied Biosystems) using the following thermal cycle rou-
tine: 50‡C for 2 min, 95‡C for 10 min, and then 40 cycles of 95‡C for
15 s, followed by 60‡C for 1 min. A comparative threshold cycle (CT)
method (User Bulletin Number 2; Applied Biosystems) was used to
determine relative gene expression. Relative quanti¢cation of PPI
mRNA was done by normalizing the PPI mRNA with the tTA
mRNA signal and by assigning a value of 100 to the normalized
sample level at time zero.
3. Results
3.1. Increase of insulin expression from transfected
HepG2 cells
Fig. 1 shows the plasmids constructed to improve insulin
expression. With the CMV promoter, vector D resulted in
insulin secretion rates of 720V 130 fmol/(hW106 cells) from
transiently transfected HepG2 hepatomas (Fig. 2). This was
32.0V 9.4-fold higher than the secretion rate achieved with the
furin-compatible insulin gene without any gene attachments
(Figs. 1 and 2, vector A), and 27.5 V 8.0-fold higher relative to
the wild-type insulin gene with the chimeric intron and SV40
enhancer (Figs. 1 and 2, vector E). However, because the
SV40 enhancer is not compatible with the tet-responsive sys-
tem, vectors applied for tet-responsive insulin expression did
not contain this sequence, but they did contain the B^C and
Fig. 1. Plasmid structures. Vectors A, B, C, D and E were con-
structed for evaluating elements that increase insulin expression.
Vector F and G are the tet-responsive plasmids with one and three
copies, respectively, of PPI cDNA.
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C^A junctions and B10 His-to-Asp mutations, as well as the
chimeric intron.
3.2. PPI mRNA engineering and expression
The control and engineered PPI mRNA expression plas-
mids (vectors F and G, Fig. 1) were each transiently co-trans-
fected with plasmid pTet-O¡ in HepG2 cells. Use of the en-
gineered PPI mRNA decreased the insulin expression level to
109V 43 fmol/(hW106 cells) from 320V 55 fmol/(h 106 cells)
(n=4) of the control construct, or by 66%. Evidently, the
decreased stability of engineered mRNA reduced intracellular
mRNA levels and thus expression, as observed in many other
nonsense mutations [14,15]. However, cells with both engi-
neered and control plasmids were regulated in a similar fash-
ion by DOX. With the control plasmid, transfected cells had a
24.8V 5.2-fold higher mRNA expression and a 20.7 V 3.8-fold
higher insulin secretion rate in the absence relative to the
presence of DOX. With the engineered plasmid, the corre-
sponding values were 20.7V 3.9-fold higher mRNA and
19.2V 4.8-fold higher insulin secretion rate in the absence vs.
presence of DOX.
3.3. Dynamics of down-regulation of insulin expression
The down-regulation of insulin gene expression was tested
using the Tet-O¡ expression system. In the dynamic test, tran-
scription was down-regulated by exposing cells at time zero to
culture medium with 1 Wg/ml DOX (Fig. 3). The engineered
PPI mRNA exhibited a faster decline with a half-life of less
than 4 h relative to the control which had a half-life of more
than 8 h. The decline of insulin secretion rate followed the
similar trends. Thus, immunoreactive insulin can be synthe-
sized from the engineered PPI mRNA, and the dynamics of
down-regulation upon switching o¡ transcription at both the
mRNA and secreted protein levels are faster with the engi-
neered PPI mRNA relative to control.
3.4. Regulation of insulin secretion using the Tet-On system
Up- and down-regulation of insulin secretion from trans-
fected HepG2 cells was tested using the Tet-On system, in
which DOX induces insulin gene expression. Using 1 h of
induction in an 8-h cycle, insulin production from the engi-
neered PPI mRNA responded to the transcriptional switches
(Fig. 4). On the other hand, insulin production from the con-
trol PPI mRNA failed to decline during the 7-h basal periods
of exposure to DOX-free medium.
3.5. Translation inhibition test
A control experiment was performed to elucidate whether
NMD was indeed involved in shortening the half-life of the
engineered PPI mRNA. Since normal mRNA and nonsense
mutants are distinguished from each other via translation, the
e¡ect of inhibiting translation on the levels of control and
engineered PPI mRNA was examined. HepG2 hepatomas
transiently transfected with control or engineered PPI
mRNA under Tet-O¡ control were maintained in DOX-free
medium and exposed to cycloheximide at time 0 (Fig. 5). The
engineered/control PPI mRNA ratio at time 0 was de¢ned as
100%. After 4 h of cycloheximide treatment, this ratio in-
creased to 490% compared to the cycloheximide-free culture.
Upon withdrawing cycloheximide to resume translation, the
engineered/control PPI mRNA ratio decreased toward the
basal level.
4. Discussion
Cell sourcing constitutes a critical issue in developing a cell-
based therapy for treatment of IDD. Non-L cells, primarily
cells of hepatic origin, are considered by several research
groups as hosts for recombinant insulin expression under
transcriptional regulation [1^5]. A major advantage of these
cells is that they are potentially autologous, retrieved as a
Table 1
Probe and primer sequences for TaqMan real-time PCR technique
Gene Probe and primer sequence (5PC3P)
Insulin FAM probe: TCCGACCTGGTGGAAGCTCTCTACCTAGTG
forward: TTTGTGAACCAACACCTGTGC
reverse: GGGTGTGTAGAAGAAGCCTCGTT
tTA VIC probe: CCCGTAAACTCGCCCAGAAGCTAGGTGT
forward: GGTCGGAATCGAAGGTTTAACA
reverse: TGCCAATACAATGTAGGCTGCT
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Fig. 2. Systematic increase of insulin expression from transfected
HepG2 hepatomas. Cells were transiently co-transfected with the
test vector shown in Fig. 1 (A, B, C, D or E) and the internal con-
trol plasmid pGL3-control. Luciferase, expressed through pGL3-
control, was used to normalize the insulin secretion rate and thus
correct for variations in transfection e⁄ciency. The normalized insu-
lin secretion rate from vector D (highest insulin expression vector)
was assigned a value of 100. Experiments were performed in tripli-
cate wells. *, # and 8 indicate P values 6 0.02, and c indicates P
value 6 0.04. P values were calculated using a one-tailed t-test, as-
suming unequal variances. Bars indicate standard deviation.
Fig. 3. Dynamics of down-regulation of insulin gene expression us-
ing Tet-O¡ system with control (open circles) and engineered (¢lled
squares) PPI mRNA expression. A: Down-regulation of PPI
mRNA. B: Down-regulation of insulin secretion rate. tTA mRNA
was used as an internal standard for quantitative PPI mRNA assay.
In each independent test, the PPI mRNA was normalized by desig-
nating the sample without DOX treatment (t=0) as the calibrator
and setting it at 100%; insulin secretion rates were normalized by
designating the sample with the highest rate as the calibrator and
setting it at 100%. After 8-h down-regulation, the control and the
engineered PPI mRNA decreased to 61V8% (P6 0.007) and
14V 10% (P6 0.003), respectively, and the insulin secretion rates to
75V 12% (P6 0.05) and 17V 7% (P6 0.002), respectively. Each ex-
periment involved three independent tests. Bars indicate standard
deviations.
FEBS 27017 13-2-03
S.-C. Tang, A. Sambanis/FEBS Letters 537 (2003) 193^197 195
biopsy from the patient. A disadvantage is that transcription-
ally controlled cells exhibit sluggish secretion dynamics and
thus may not be suitable, as such, for achieving normoglyce-
mia in higher diabetic animals and humans. To expedite the
dynamics of secretion down-regulation, translation needs to
stop soon after transcription has been turned o¡.
The topic of modulation of mRNA stability is currently
under intense investigation [18^20]. Speci¢cally with PPI
mRNA, to accelerate the rate of mRNA turnover, the use
of antisense RNA [21] or connecting the insulin gene with
the 3P-untranslated region (3P-UTR) of some labile mRNAs,
such as those encoding cytokines, have been considered [7].
Compared to these, our approach involving NMD is simple
and straightforward. It is also expected to be generic and ap-
plicable to di¡erent host cells, including primary cells.
NMD improved the secretory response of HepG2 cells but
also reduced intracellular PPI mRNA levels and thus insulin
expression. To ameliorate this problem, we increased insulin
expression before applying NMD. HepG2 hepatomas transi-
ently transfected with vector D (Fig. 1) secreted insulin at a
rate of 720 fmol/(hW106 cells), which is higher than the basal
insulin secretion rate of 380 fmol/(hW106 cells) exhibited by
LTC-3 mouse insulinomas [22]. For tet-responsive insulin ex-
pression, although the SV40 enhancer was not applied, the
insulin secretion from Tet-O¡ transfected HepG2 in DOX-
free medium was 320 fmol/(hW106 cells) and 109 fmol/(hW106
cells) when the control and engineered PPI mRNA, respec-
tively, were used.
The speci¢city of the Tet-O¡ system and the sub-toxic
DOX concentration used in this study [23] increase the ¢delity
of mRNA half-life measurements compared to experiments
with non-speci¢c inhibitors [24]. One concern in determining
insulin secretion dynamics with the tet-responsive system is
the pharmacokinetics of DOX. It has been shown that the
Tet-O¡ system and its transcription repressor tetracycline
can be applied to measure the stability of a spliced intron
with a half-life as low as 6 min [25]. Hence, it appears that
tetracycline quickly di¡uses into cells and blocks transcrip-
tion. We expect DOX, a tetracycline isomer and analog, to
have similar kinetics in regulating insulin gene expression in
HepG2. However, the reverse process of decline of intracellu-
lar DOX concentration may be more complicated since, be-
sides di¡usion out, processes such as dissociation of DOX
from the DOX^protein complex, distribution and accumula-
tion of DOX in organelles, and metabolism of DOX may be
occurring and contributing to the delays in insulin secretion
down-regulation exhibited by the Tet-On system (Fig. 4). It is
possible that with a metabolizable secretagogue, e.g. glucose,
the intrinsic kinetics of transcription are closer to the kinetics
of secretion, especially during the down-regulation process.
In Fig. 4, we applied two DOX square waves to induce the
Tet-On system, and obtained a 5-fold increase of insulin se-
cretion from the single copy plasmid. We have also performed
an 8-h induction with the same Tet-On system, and obtained
an approximately 30-fold increase of insulin secretion (data
not shown). This result is similar to the ¢ndings of Gossen et
al. [23] using luciferase as the reporter to test the kinetics of
the Tet-On system. Due to the stability of the one-copy PPI
mRNA plasmid, there was no decline in insulin secretion rate
during the two 7 h DOX-free basal periods. However, the
increase in insulin secretion from the second induction was
signi¢cantly lower than the ¢rst. If the experiment continued
in the same fashion, we would expect the insulin secretion to
not exhibit any net increase after some maximum, as any
(small) additional increase in secretion rate upon induction
would be compensated by a decline during the subsequent
basal period.
This work constitutes a ¢rst step towards developing poten-
tially autologous, genetically engineered, transcriptionally
controlled non-L cells for treatment of IDD. Clearly, the
NMD-mediated improvement of secretion dynamics will
need to be validated in primary cells expressing insulin under
a glucose-responsive promoter. In this, it is important that the
host cells and the insulin gene be of the same species, as
species mismatch may alter the stability of PPI mRNA con-
siderably. It should be noted, however, that there exists no
evidence that the NMD methodology would not be applicable
to primary cells. Finally, the recombinant cells will need to be
studied in an in vivo situation, as the insulin secretion dynam-
ics might be di¡erent in culture and in vivo.
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Fig. 4. Regulation of insulin secretion from transfected HepG2 cells
using the Tet-On system with control (open circles) and engineered
(¢lled squares) PPI mRNA expression. In each independent test, the
insulin secretion rates were normalized by designating the sample
with the highest rate as the calibrator and setting it at 100%. Each
experiment involved three independent tests. Bars indicate standard
deviations.
 
  
 
Fig. 5. E¡ect of translation on PPI mRNA stability (evidence of
NMD). HepG2 hepatomas were transiently co-transfected with
pTet-O¡ and the control or engineered PPI mRNA expression plas-
mid. tTA mRNA was used as an internal standard for quantitative
PPI mRNA assay. In each independent test, the PPI mRNA ratios
(engineered/control) were normalized against the sample without cy-
cloheximide treatment (t=0), which was set at 100%. Each experi-
ment involved four independent tests. * and # indicate P values
6 0.003, and c indicates P value = 0.36. Bars indicate standard devi-
ations.
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